Treatment
Cell clinical trials
We’re tracking 5,550 recruiting studies that include Cell, each written for real people, not researchers, below.
Recruiting studies
- NCT04857164RecruitingPhase 2
Pembrolizumab plus chemotherapy for recurrent or metastatic throat cancer
This trial tests whether pembrolizumab (an immunotherapy) combined with chemotherapy works better as a first treatment for recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) in the oral/throat area. It aims to improve cancer control and help people live longer with fewer side effects than standard care.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07457528RecruitingPhase 2
Chemo, radiation, and immune therapy before surgery for esophageal cancer
This trial tests a combination of chemotherapy, radiation, and two targeted drugs (serplulimab and nimotuzumab) given before surgery for a certain type of esophageal cancer. It aims to see if this approach can safely improve outcomes.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT07455942Recruiting
Understanding why anal cancer diagnosis is delayed
This study looks at the reasons and delays in diagnosing anal cancer. It aims to help doctors detect it earlier in the future.
AngersAges 18 years+ - NCT07461090Recruiting
Laparoscopic vs. open kidney removal surgery study
This study compares laparoscopic (keyhole) and open surgery for removing all or part of a kidney. It looks at how well each method works and how much it costs, to help decide which is better for patients with certain kidney conditions or tumors.
Shibīn al Kawm, Shebin ElkomAges 1 year+ - NCT07454226Recruiting
Drug combo for Ph-like acute lymphoblastic leukemia
This trial tests a combination of targeted drugs (ABL/JAK inhibitors) with chemotherapy and venetoclax for people with a type of leukemia called Ph-like ALL. It aims to see if this treatment is safe and effective.
Tianjin, Tianjin MunicipalityAges 14–60 - NCT07457346RecruitingPhase 2
Testing emactinib with chemo and immunotherapy before head and neck cancer surgery
This trial tests whether combining the drug emactinib with chemotherapy and immunotherapy before surgery helps treat advanced head and neck cancer. It aims to shrink tumors and make surgery more effective.
Hangzhou, ZhejiangAges 18–75 - NCT06795958Recruiting
Detecting heart rejection without a biopsy in children
This trial tests if a special MRI can detect early signs of heart rejection in children and young adults who have had a heart transplant. If successful, it might reduce the need for invasive biopsies.
BolognaAges Up to 18 years - NCT06729346Recruiting
Finding hidden tumors during bladder cancer surgery
This study tests if a special light (NBI) can find bladder tumors that standard white light misses during surgery. It may help ensure more complete tumor removal.
Rawalpindi, Punjab ProvinceAges 18–75 - NCT03382158Recruiting
Learn about DICER1-related tumors through a patient registry
This registry collects information about people with known or suspected DICER1-related conditions, including certain rare chest and other tumor types. It helps doctors and researchers understand these conditions better and may support future studies.
Minneapolis, MinnesotaAges birth–100 years - NCT05819346Recruiting
Digital lifestyle program for lung cancer survivors
This trial tests a phone/tablet-based lifestyle program for people who have finished lung cancer treatment. It may help survivors improve health and daily habits after non-small cell lung cancer.
BarmelweidAges 18 years+ - NCT06781450Recruiting
Study of immunotherapy for relapsed chest lymphoma
This study looks at how well two immunotherapy medicines—pembrolizumab alone or nivolumab combined with brentuximab vedotin—work for people with a type of lymphoma in the chest that has come back or not responded to treatment. It uses real-world data from patients who received these treatments outside of a clinical trial.
Bologna, BolognaAges 18 years+ - NCT07452601RecruitingPhase 2
Timing of immunotherapy infusion in chemo before surgery for esophageal cancer
This trial tests whether giving immunotherapy and chemotherapy at a specific time of day improves outcomes for people with esophageal cancer before surgery. It may help shrink the tumor and make surgery more effective.
Xi'an, ShannxiAges 18–75 - NCT07451652RecruitingPhase 2
Low dose epcoritamab plus chemotherapy for relapsed lymphoma
This trial tests a combination of a lower dose of the immunotherapy drug epcoritamab with standard chemotherapy (GemOx) for people with a type of lymphoma called DLBCL that has come back or not responded to previous treatment. The goal is to see if this combination can help get the lymphoma under control before a stem cell transplant (using your own cells).
Monterrey, Nuevo LeónAges 18–65 - NCT07450040Enrolling by invitation
Tislelizumab plus chemo for early-stage NK/T-cell lymphoma
This trial tests a combination of the immunotherapy drug tislelizumab with two chemotherapy drugs (gemcitabine and peraspartase) for people with newly diagnosed stage I or II NK/T-cell lymphoma. The goal is to see if this combination works well and is safe.
Shanghai, ChinaAges 18–70 - NCT07452003Recruiting
Immunotherapy plus chemo before and after lung cancer surgery
This trial tests a new combination of an immunotherapy drug (QL1706) plus chemotherapy given before and after surgery for people with certain stages of non-small cell lung cancer (NSCLC). The goal is to see if this approach helps shrink the tumor and improves outcomes.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07451613RecruitingPhase 1/Phase 2
Stem cell therapy trial for Huntington's disease
This trial tests whether human neural stem cells are safe and tolerable for people with Huntington's disease. It involves a neurosurgical procedure to inject the cells into the brain, along with MRI scans and other monitoring.
Irvine, CaliforniaAges 18–65 - NCT03740503Recruiting
Study genes in people who respond unusually to treatment
This study looks at stored tumor samples to understand why some people respond much better or much worse than expected. The goal is to learn what the tumor’s genes might be telling doctors about response to treatment.
Toronto, OntarioAges 18 years+ - NCT06803199Recruiting
LH and FSH effects on cell metabolism in IVF
This trial looks at how two hormones, LH and FSH, affect the way cells around your eggs use energy. It may help doctors personalize IVF treatment for women your age.
Kaohsiung CityAges 35–40 - NCT06805448RecruitingPhase 1/Phase 2
Stem cell treatment for dry mouth in Sjögren's disease
This trial tests if injecting fat-derived stem cells into the salivary glands can help relieve dry mouth in people with Sjögren's disease. It aims to improve saliva flow and reduce discomfort.
CopenhagenAges 18 years+ - NCT06806488Recruiting
Marginal zone lymphoma patient study
This study looks at patients with marginal zone lymphoma who were diagnosed and treated at a specific hospital in Italy between 2012 and 2018. It aims to learn more about how the disease progresses and how patients respond to treatment.
Bologna, BolognaAges 18 years+ - NCT07435779RecruitingEarly Phase 1
CAR-T cell therapy for severe ulcerative colitis
This trial tests a new treatment using your own immune cells (called CAR-T cells) to calm down the immune attack that causes ulcerative colitis. It is for people with moderate to severe colitis who have not gotten better with standard medicines.
GuangzhouAges 18–60 - NCT07439653RecruitingPhase 1/Phase 2
Testing TORL-5-700 for advanced lymphoma
This trial tests a new treatment called TORL-5-700 for people with certain types of non-Hodgkin lymphoma that have not responded to other treatments. The goal is to see how safe it is and how well it works.
Fullerton, CaliforniaAges 18 years+ - NCT07442851Recruiting
SickleFit exercise and nutrition study for sickle cell
This study looks at whether a personalized exercise and nutrition program can help people with sickle cell disease feel better and have fewer pain crises. It is for adults 35 and older with any type of sickle cell disease.
Durham, North CarolinaAges 35 years+ - NCT07441291RecruitingPhase 3
CAR-T vs donor immune cells for residual leukemia after transplant
This study tests whether a therapy using your own immune cells (CAR-T) works better than donor immune cells (DLI) to remove leftover leukemia cells after a stem cell transplant. The goal is to prevent the leukemia from coming back.
Beijing, ChinaAges 3–79
Common questions
- Are there clinical trials studying Cell?
- Yes. Clin2 currently lists 5,550 recruiting studies that include Cell, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Cell trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Cell an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Cell or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.